Since August, the medical service sector has accelerated. The Shenwan Medical Service Index has accumulated a cumulative increase of 23.45% during the month and 41.55% during the year. Among the constituent stocks, Baiaosetu, Pharmaceutical, Wanbang Pharmaceuticals, and Innox have all doubled their cumulative gains since this year, while the leading drug, Mingkang, rose 87.38%. According to market analysts, the current sector market mainly benefits from the continued release of policy dividends, compounded by confirmation of industry fundamentals and profit inflection points. The popularity of the sector is also confirmed by financing funds. As of August 17, the net financing purchases of Zhaoyan Pharmaceutical and Yakang Biotech have all exceeded 200 million yuan since this year; the net financing amount of the four individual stocks of Wanbang Pharmaceutical, Baiosetu, International Medicine, and Bide Pharmaceutical has exceeded 100 million yuan, and the financing capital's attention to the sector has increased markedly. In terms of performance, based on the median statistics of semi-annual reports, express reports, and forecasts, the net profit of the eight companies exceeded 100 million yuan in the first half of the year. Among them, Pharmaceutical Kangde ranked first, with net profit reaching 11.08 billion yuan; Kanglong Chemical, Zhaoyan New Pharmaceutical, Tongce Healthcare, and Jiuzhou Pharmaceutical had net profits of 750 million yuan, 750 million yuan, 458 million yuan, and 387 million yuan respectively.

Since August, the medical service sector has accelerated. The Shenwan Medical Service Index has accumulated a cumulative increase of 23.45% during the month and 41.55% during the year. Among the constituent stocks, Baiaosetu, Pharmaceutical, Wanbang Pharmaceuticals, and Innox have all doubled their cumulative gains since this year, while the leading drug, Mingkang, rose 87.38%. According to market analysts, the current sector market mainly benefits from the continued release of policy dividends, compounded by confirmation of industry fundamentals and profit inflection points. The popularity of the sector is also confirmed by financing funds. As of August 17, the net financing purchases of Zhaoyan Pharmaceutical and Yakang Biotech have all exceeded 200 million yuan since this year; the net financing amount of the four individual stocks of Wanbang Pharmaceutical, Baiosetu, International Medicine, and Bide Pharmaceutical has exceeded 100 million yuan, and the financing capital's attention to the sector has increased markedly. In terms of performance, based on the median statistics of semi-annual reports, express reports, and forecasts, the net profit of the eight companies exceeded 100 million yuan in the first half of the year. Among them, Pharmaceutical Kangde ranked first, with net profit reaching 11.08 billion yuan; Kanglong Chemical, Zhaoyan New Pharmaceutical, Tongce Healthcare, and Jiuzhou Pharmaceutical had net profits of 750 million yuan, 750 million yuan, 458 million yuan, and 387 million yuan respectively.